STOCK TITAN

EyePoint Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 2, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
EyePoint Pharmaceuticals to report Q2 2023 financial results and highlight recent corporate developments
Positive
  • EyePoint Pharmaceuticals will host a conference call and live webcast to report its Q2 2023 financial results and highlight recent corporate developments
Negative
  • None.

WATERTOWN, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 2, 2023 to report its second quarter 2023 financial results and highlight recent corporate developments.

To access the live conference call, please register using the audio conference link: https://register.vevent.com/register/BI1f9c401d832f439690f47dc2454e01d6. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (NASDAQ: EYPT) is a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary erodible Durasert E™ technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials. The proven Durasert® drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. For more information visit www.eyepointpharma.com.

Investors:
Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com

Media Contact
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com


FAQ

When will EyePoint Pharmaceuticals report its Q2 2023 financial results?

EyePoint Pharmaceuticals will report its Q2 2023 financial results on Wednesday, August 2, 2023.

How can I access the live conference call?

You can access the live conference call by registering using the audio conference link provided in the PR.

Where can I access the live audio webcast?

You can access the live audio webcast via the Investors section of the EyePoint Pharmaceuticals website.

Will there be a webcast replay available?

Yes, a webcast replay will be available on the corporate website at the conclusion of the call.

EyePoint Pharmaceuticals, Inc.

NASDAQ:EYPT

EYPT Rankings

EYPT Latest News

EYPT Stock Data

939.60M
30.74M
1.02%
104.69%
13.74%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
WATERTOWN

About EYPT

psivida corp., (nasdaq: psdv) (asx: pva) headquartered in watertown, ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. psivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, durasert™ and biosilicon™. the injectable, sustained release micro-insert iluvien® for the treatment of chronic diabetic macula edema (dme), licensed to alimera sciences, inc., has received marketing authorization in austria, france, germany, portugal, the u.k. spain, and italy. iluvien for dme has recently been approved in the us. psivida plans to institute pivotal phase iii clinical trials for the treatment of posterior uveitis with the same micro-insert as iluvien for dme. an investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. psivida's two fda-approved products, retisert®